Form 4: Edgewise Therapeutics Executive Alan Russell Executes Stock Option and Sells Shares
SEC Form 4
Alan Russell, Chief Scientific Officer of Edgewise Therapeutics, exercised stock options and sold 200 shares of common stock at an average price of $30.02.
Summary
- On March 7, 2025, Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, exercised a stock option to acquire 200 shares of common stock at a price of $0.18 per share.
- Simultaneously, Russell sold 200 shares of common stock at an average price of $30.02, with individual sales ranging from $30.00 to $30.04.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2024.
- Following these transactions, Russell directly owns 14,863 shares of Edgewise Therapeutics common stock and derivative securities representing the right to buy 1,456,580 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity under a pre-arranged plan. No indication of positive or negative implications for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives and their potential alignment with shareholder interests. The use of a 10b5-1 plan suggests a pre-arranged strategy to avoid accusations of trading on inside information.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
- Rule 10b5-1 plans are commonly used by executives to schedule stock sales in advance, mitigating concerns about insider information.
- The reported transactions are typical for executives holding stock options and managing their personal investment portfolios.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small volume of shares sold.
- The disclosure provides transparency to stakeholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of adoption of Rule 10b5-1 Plan |
| 03/07/2025 | Date of stock option exercise and stock sale |
| 03/11/2025 | Date of Form 4 filing |
| 06/27/2032 | Expiration date of stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.